VEGFA and glioblastoma: Interestingly, in the double-blinded phase II ReACT trial, assessing safety, 6-months PFS, PFS, OS, and ORR of rindopepimut® plus the vascular endothelial growth factor (VEGF)-neutralizing antibody bevacizumab versus bevacizumab plus control in 73 cases of relapsed EGFRvIII-positive GBM, demonstrated a prolonged OS by rindopepimut® (NCT01498328) [70].